Genmab A/S and BioNovion struck a deal to evaluate several DuoBody product candidates targeting immune checkpoints.
The companies announced that they have entered into a co-development and commercialization agreement to evaluate the product candidates. Genmab and BioNovion will contribute panels of antibodies for the creation of bispecific antibody products using Genmab’s DuoBody platform technology.
Genmab’s DuoBody technology is its proprietary platform for bispecific antibody generation. The innovative platform was created for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies, allowing DuoBody molecules to be administered and dosed as other antibody therapeutics.
Under the agreement, if the companies jointly select a product candidate for clinical development, costs associated with development will be shared equally, with each company retaining a 50 percent share of the product rights. If one company opts out, the other company is entitled to continue developing the product at predefined licensing terms. The agreement also includes terms which allow the companies to opt out of joint development at key points in each product’s development.
“We are pleased to expand our research collaboration with BioNovion into a full commercial agreement, and utilize our robust and versatile DuoBody technology to create unique differentiated cancer therapeutics in the promising field of immuno-oncology,” said Genmab’s Chief Executive Officer Jan van de Winkel, PhD.
In addition to BioNovion, companies including Eli Lilly, Janssen, Novartis and Cormorant Pharmaceuticals have all partnered with Genmab for its DuoBody technology platform.
Source: Genmab A/S